EXTON, PA -- (MARKET WIRE) -- January 26, 2007 -- Rheologics, Inc., a subsidiary of Rheologics Technologies, Inc. (PINKSHEETS: RTGI) ("Rheologics"), today announced the initiation of a Phase I study to explore the effect of lowering blood viscosity in patients with critical limb ischemia and end-stage peripheral vascular disease. The study is taking place at the Seoul Veterans Hospital in Seoul, South Korea utilizing the Rheolog® blood viscometer.
